ClinicalTrials.gg
CompletedNCT06297616Updated Jan 16, 2026

A Study of LY3841136 in Japanese Participants With Obesity or Overweight

A Phase 1 interventional study of LY3841136 and LY3841136-Placebo in Obesity and Overweight, sponsored by Eli Lilly and Company. Completed at 3 sites in Japan. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-01-16.

Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
128
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 22 studies testing eloralintide in Obesity — 14 open to participants now, 15 under way, 8 of them phase 3. eloralintide · Obesity.

Enrollment
16th of 22
128 · median 315
Started
2024
with 3 others
Phase 1
9 of 22
4 open now
Registered
4th of 22
by date
Lead sponsor
22 of 22
Eli Lilly and Company

Among the 22 studies testing eloralintide in Obesity, this one is the 16th largest by enrollment, is one of 4 that started in 2024, is one of 9 in phase 1, and was the 4th registered.

Obesity

11,543 studies on the registry are indexed under Obesity; 2,042 are open to participants now.

Browse Obesity studies →

Open to participants now

14 of the 22 studies testing eloralintide in Obesity are open now, in 12 countries. Recruiting first, the newest first:

9 more — sign in →

By country, each count listing its studies:

All 14 open studies →

About eloralintide

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 1,339 Obesity studies recruiting now, 377 (28%) set no upper age limit and 859 (64%) stop at 75 or younger; 167 take children under 18; 490 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies testing eloralintide in Obesity, or all of them as a file.
02

Study summary

The main purpose of this study is to learn about the side effects of LY3841136 alone and in combination with tirzepatide, when given to Japanese participants with obese or overweight. Blood tests will be performed to investigate how the body processes the study drug and how the study drug affects the body. Part A of the study will last about 28 weeks and may include up to 17 visits. Part B of the study will last about 40 weeks and may include up to 29 visits.

03

Conditions studied

  • Obesity
  • Overweight

Keywords

  • Obesity Disease
  • Metabolic Disorders
  • Body Weight Loss
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female participants who agree to requirements
  • Have a (BMI) within the range of 27 to 40 kg/m², inclusive
  • Have had a stable weight for the 3 months

Exclusion criteria

Exclusion Criteria:

  • Have a history of significant atopy (severe allergic manifestations), multiple or severe drug allergies, or severe posttreatment reactions
  • Have a history or presence of psychiatric disorders, including a history of major depressive disorder or severe psychiatric disorders such as schizophrenia, bipolar disorder within the last 3 years
  • Have been diagnosed with Type 1 or Type 2 Diabetes Mellitus
  • Have a history of chronic medical conditions involving the heart, liver, or kidneys
  • Have a history of any within the past 5 years
  • Have a history or presence of a GI disorder
  • Have had within the last 6 months, or plan to have during the study, a device-based or surgical treatment use for obesity
  • Have been treated, or plan to be treated, with prescription medications or other non-approved drugs intended to promote weight loss, within 3 months prior to screening
  • For participants in Part B, have previously received tirzepatide within 6 months prior to screening
  • For participants in Part B, have a personal or family history of medullary thyroid carcinoma, or have multiple endocrine neoplasia syndrome type 2
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
128 participants (actual)

Study arms

  • Experimental
    Part A: LY3841136

    LY3841136 administered subcutaneously (SC)

    Drug: LY3841136

  • Placebo comparator
    Part A: Placebo

    Placebo administered SC

    Drug: LY3841136-Placebo

  • Experimental
    Part B: Tirzepatide + LY3841136-Placebo

    Tirzepatide administered SC along with volume-matched LY3841136-Placebo administered SC

    Drug: LY3841136-Placebo · Drug: Tirzepatide

  • Experimental
    Part B: LY3841136 + Tirzepatide-Placebo

    LY3841136 administered SC along with volume-matched Tirzepatide-Placebo administered SC

    Drug: LY3841136 · Drug: Tirzepatide-Placebo

  • Experimental
    Part B: LY3841136 + Tirzepatide

    LY3841136 administered SC along with Tirzepatide administered SC

    Drug: LY3841136 · Drug: Tirzepatide

  • Placebo comparator
    Part B: LY3841136-Placebo + Tirzepatide-Placebo

    Volume-matched LY3841136-Placebo administered SC along with volume-matched Tirzepatide-Placebo administered SC

    Drug: LY3841136-Placebo · Drug: Tirzepatide-Placebo

Interventions

  • Administered SC

  • DrugLY3841136-Placebo

    Administered SC

  • Administered SC

  • DrugTirzepatide-Placebo

    Administered SC

06

What researchers measure

Primary outcomes

  1. Part A: Number of Participants with One or More Serious Adverse Events (SAE) Considered by the Investigator to be Related to Study Drug Administration at Week 22

    A summary of treatment emergent adverse events (TEAEs), SAEs and other non-serious adverse events (AEs), regardless of causality, will be reported in the Reported Adverse Events module

    Time frame: Baseline through Week 22

  2. Part B: Number of Participants with One or More Serious Adverse Events (SAE) Considered by the Investigator to be Related to Study Drug Administration at Week 34

    A summary of treatment emergent adverse events (TEAEs), SAEs and other non-serious adverse events (AEs), regardless of causality, will be reported in the Reported Adverse Events module

    Time frame: Baseline through Week 34

Secondary outcomes

  1. Part A Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve (AUC) of LY3841136

    PK: AUC of LY3841136 alone

    Time frame: Predose through Week 22

  2. Part A PK: Maximum Observed Concentration (Cmax) of LY3841136

    PK: Cmax of LY3841136 alone

    Time frame: Predose through Week 22

  3. Part A Pharmacodynamics (PD): Change From Baseline in Body Weight at Week 12

    PD: Change from baseline in body weight

    Time frame: Baseline through Week 12

  4. Part B PK: AUC of LY3841136 in Combination with Tirzepatide

    PK: AUC of LY3841136 in combination with tirzepatide

    Time frame: Predose through Week 34

  5. Part B PK: Cmax of LY3841136 in Combination with Tirzepatide

    PK: Cmax of LY3841136 in combination with tirzepatide

    Time frame: Predose through Week 34

  6. Part B PD: Change From Baseline in Body Weight at Week 24

    PD: Change from baseline in body weight

    Time frame: Baseline through Week 24

07

Study locations

3 sites
  • P-One Clinic
    Hachiōji, Tokyo 192-0071, Japan
  • Sumida Hospital
    Sumida-ku, Tokyo 130-0004, Japan
  • Hakata Clinic
    Fukuoka, 812-0025, Japan
08

References and documents

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2024 to primary completion in Nov 2025, 19 months.

Of 334 industry-sponsored phase 1 interventional studies under Obesity, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 15. This study's 19 months is above that.

Counting every sponsor, half of 439 studies reached it within 11 months; a quarter within 6 and three quarters within 24.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 1, 2024
First posted
Mar 7, 2024
StartActual
Apr 15, 2024
Primary completionActual
Nov 21, 2025
CompletionActual
Nov 21, 2025
Last update
Jan 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 16, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06297616
Responsible party
Sponsor
First posted
Mar 7, 2024
Start date
Apr 15, 2024
Primary completion
Nov 21, 2025
Completion
Nov 21, 2025
Last update
Jan 16, 2026

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Eloralintide

Start the discussion